Kimia Biosciences

What Kimia Biosciences does

Kimia Biosciences is a publicly listed Indian manufacturer of bulk drugs (active pharmaceutical ingredients, or APIs) targeting high-potential therapeutic segments. Founded in 1993 and headquartered in New Delhi, the company operates in the small-molecule API space with 101–250 employees and trades on the Bombay Stock Exchange under the ticker KIMIABL. Its stated value proposition centers on supplying API material to downstream pharmaceutical formulators, particularly in therapeutic areas where demand is expected to outpace industry averages.

The business model is that of a contract/commercial API manufacturer: revenue is generated by selling manufactured drug substances to formulation companies, with pricing typically negotiated on a per-kilogram or per-batch basis against regulatory specifications (e.g., GMP, DMF-supported filings). Customer segments are pharmaceutical companies, both domestic Indian formulators and, based on the regulatory profile typical of API exporters, international generic-drug manufacturers; however, specific customer names, contract structures, and pricing terms were not disclosed in the available data. Distribution is global in principle for API exporters but no specific channels, geographic footprint, or commercial partnerships were provided.

Financial reporting shows a five-year span in which revenue contracted from approximately ₹16,447M (FY22) to roughly ₹12,304M (FY26), while profitability transitioned from sustained net losses through FY24 to positive net income in FY25–FY26, with EBITDA expanding materially in FY25. The data flow into the input was limited (the firmographic, product, customer, and partnership fields were largely empty, and the company website returned a verification placeholder rather than substantive content), so the description above reflects only what is supported by the supplied firmographics, leadership roster, and financial table.

Name

Kimia Biosciences

Website

https://kimiabiosciences.com

Company type

Private

Founded year

1993

Headcount range

101–250 employees

Short description

Kimia Biosciences is an Indian manufacturer of bulk drugs and active pharmaceutical ingredients (APIs), founded in 1993 and headquartered in New Delhi. Publicly listed on the BSE (ticker KIMIABL), the company serves pharmaceutical formulators across high-potential therapeutic segments.

Ownership category

akta.pro rank

Headquarters

HQ city

New Delhi

HQ country

India

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D

Core offering

Kimia Biosciences is a manufacturer of bulk drugs (active pharmaceutical ingredients) focused on high-potential therapeutic segments. The company produces pharmaceutical raw materials and intermediates that are supplied to drug formulators and pharmaceutical companies for use in finished dosage formulations. It is publicly listed on the Bombay Stock Exchange.

Differentiator

Problem solved

Functional benefit

Products and services

• Bulk drugs (Active Pharmaceutical Ingredients)

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights2 records

Direct peers

• Ajanta Pharma: Indian pharmaceutical manufacturer focused on formulations with select API exposure. Comparable smaller-cap Indian pharma peer in therapeutic segment focus and India-based manufacturing.
• Divi's Laboratories: India's leading pure-play API manufacturer serving global innovator and generic customers. Most directly comparable in core focus on bulk drugs/active pharmaceutical ingredients and exports to regulated markets.
• Granules India: Indian manufacturer of active pharmaceutical ingredients and finished formulations for global generics customers. Directly comparable in product category (APIs + formulations) and small/mid-cap India-based scale.
• Lupin: Major Indian pharmaceutical company with significant API manufacturing operations alongside finished formulations. Comparable in segment focus (Indian pharma manufacturer with API exposure) and global generics customers.
• Torrent Pharmaceuticals: Indian pharmaceutical company with API and finished formulation operations across therapeutic segments. Comparable in product category, India-base, mid-cap scale profile, and global generics focus.
• Cadila Healthcare (Zydus): Large Indian pharmaceutical manufacturer with API and finished formulation operations. Comparable in product category (bulk drugs and formulations) and India-based manufacturing model targeting regulated markets.
• Aurobindo Pharma: One of India's largest API and finished formulation manufacturers with global generics footprint. Directly comparable in product category (bulk drugs and formulations), Indian-base operating model, and target customer base (global generic pharma customers).
• Dr. Reddy's Laboratories: Indian pharmaceutical company with substantial API manufacturing operations alongside finished generics. Directly comparable in product category (APIs and formulations), India-base, and global export orientation.

Broad incumbents

• Sun Pharmaceutical Industries: India's largest pharmaceutical company with broad finished dosage and API portfolio. Comparable industry positioning but operates at materially larger scale with broader product mix and global commercial infrastructure.
• Cipla: Major Indian pharmaceutical manufacturer with global reach in finished formulations. Comparable in pharma manufacturing focus and India base but with broader finished-product orientation and larger scale.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

• Xx.com/kimiabiosci

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kimia Biosciences